Literature DB >> 15169916

Protein inhibitor of activated STAT Y (PIASy) and a splice variant lacking exon 6 enhance sumoylation but are not essential for embryogenesis and adult life.

Kelly A Wong1, Rachel Kim, Heather Christofk, Jing Gao, Gregory Lawson, Hong Wu.   

Abstract

Protein inhibitor of activated STAT Y (PIASy) is the shortest member of the PIAS family and has been reported to modulate the transcriptional activities of STAT1, lymphoid enhancer factor 1 (LEF-1), and the androgen receptor. PIAS proteins have also been identified as E3 ligases for the small ubiquitin-like modifier (SUMO) proteins. PIASy in particular has been reported to mediate SUMO-2/3 modification of LEF-1, sequestering it into nuclear bodies, and SUMO-1 ligation to c-Myb, modulating its transcriptional activation properties. We have cloned murine Piasy and a splice variant which omits exon 6, containing the nuclear retention PINIT motif. Cell culture studies indicate that both the full length and the splice variant are localized in the nucleus but differentially enhance SUMO ligation. To further understand the functions of PIASy, we have generated PIASy-deficient mice. Surprisingly, Piasy(-/-) mice appear phenotypically normal. Activation of STAT1 is not significantly perturbed in Piasy(-/-) cells, and sumoylation patterns for SUMO-1 or SUMO-3 modification are similar when comparing tissues and embryonic fibroblasts from wild-type and knockout mice. Our study demonstrates that at steady state, PIASy is either dispensable or compensated for by other PIAS family members or by other mechanisms when deleted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15169916      PMCID: PMC419860          DOI: 10.1128/MCB.24.12.5577-5586.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  35 in total

1.  SUMO-1 modification activates the transcriptional response of p53.

Authors:  M S Rodriguez; J M Desterro; S Lain; C A Midgley; D P Lane; R T Hay
Journal:  EMBO J       Date:  1999-11-15       Impact factor: 11.598

Review 2.  Modulation of STAT signaling by STAT-interacting proteins.

Authors:  K Shuai
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

Review 3.  SUMO--nonclassical ubiquitin.

Authors:  F Melchior
Journal:  Annu Rev Cell Dev Biol       Date:  2000       Impact factor: 13.827

4.  SUMO-1 modification of bovine papillomavirus E1 protein is required for intranuclear accumulation.

Authors:  D Rangasamy; K Woytek; S A Khan; V G Wilson
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

5.  Role of SUMO-1-modified PML in nuclear body formation.

Authors:  S Zhong; S Müller; S Ronchetti; P S Freemont; A Dejean; P P Pandolfi
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

6.  A transcriptional corepressor of Stat1 with an essential LXXLL signature motif.

Authors:  B Liu; M Gross; J ten Hoeve; K Shuai
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

7.  Bovine papillomavirus E1 protein is sumoylated by the host cell Ubc9 protein.

Authors:  D Rangasamy; V G Wilson
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

8.  Cloning and analysis of a murine PIAS family member, PIASgamma, in developing skin and neurons.

Authors:  S Sturm; M Koch; F A White
Journal:  J Mol Neurosci       Date:  2000 Feb-Apr       Impact factor: 3.444

9.  Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3.

Authors:  H Saitoh; J Hinchey
Journal:  J Biol Chem       Date:  2000-03-03       Impact factor: 5.157

10.  PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1.

Authors:  A M Ishov; A G Sotnikov; D Negorev; O V Vladimirova; N Neff; T Kamitani; E T Yeh; J F Strauss; G G Maul
Journal:  J Cell Biol       Date:  1999-10-18       Impact factor: 10.539

View more
  37 in total

Review 1.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

Review 2.  SUMO wrestling with type 1 diabetes.

Authors:  Manyu Li; Dehuang Guo; Carlos M Isales; Decio L Eizirik; Mark Atkinson; Jin-Xiong She; Cong-Yi Wang
Journal:  J Mol Med (Berl)       Date:  2005-04-02       Impact factor: 4.599

Review 3.  Negative regulation of cytokine signaling.

Authors:  Akihiko Yoshimura
Journal:  Clin Rev Allergy Immunol       Date:  2005-06       Impact factor: 8.667

4.  PIASy mediates SUMO-2 conjugation of Topoisomerase-II on mitotic chromosomes.

Authors:  Yoshiaki Azuma; Alexei Arnaoutov; Tadashi Anan; Mary Dasso
Journal:  EMBO J       Date:  2005-06-02       Impact factor: 11.598

Review 5.  DNA topoisomerase II and its growing repertoire of biological functions.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

Review 6.  Protein sumoylation in brain development, neuronal morphology and spinogenesis.

Authors:  Carole Gwizdek; Frédéric Cassé; Stéphane Martin
Journal:  Neuromolecular Med       Date:  2013-08-02       Impact factor: 3.843

Review 7.  SUMO rules: regulatory concepts and their implication in neurologic functions.

Authors:  Mathias Droescher; Viduth K Chaugule; Andrea Pichler
Journal:  Neuromolecular Med       Date:  2013-08-30       Impact factor: 3.843

Review 8.  SUMO modification of DNA topoisomerase II: trying to get a CENse of it all.

Authors:  Ming-Ta Lee; Jeff Bachant
Journal:  DNA Repair (Amst)       Date:  2009-02-20

9.  Specific domain structures control abscisic acid-, salicylic acid-, and stress-mediated SIZ1 phenotypes.

Authors:  Mi Sun Cheong; Hyeong Cheol Park; Mi Ju Hong; Jiyoung Lee; Wonkyun Choi; Jing Bo Jin; Hans J Bohnert; Sang Yeol Lee; Ray A Bressan; Dae-Jin Yun
Journal:  Plant Physiol       Date:  2009-10-16       Impact factor: 8.340

10.  Spatial interplay between PIASy and FIP200 in the regulation of signal transduction and transcriptional activity.

Authors:  Nadine Martin; Klaus Schwamborn; Henning Urlaub; Boyi Gan; Jun-Lin Guan; Anne Dejean
Journal:  Mol Cell Biol       Date:  2008-02-19       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.